All lobbying filings

TODD STRATEGY GROUP

Lobbying for NOVARTIS, INC. · â€‹Multinational biopharmaceutical company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Apr 21, 2025

Official filing document

Bills named in this filing 3

HR 5376
Impacts and Outcomes for Health Career Training Act
HR 1672
Maintaining Investments in New Innovation Act
HR 946
ORPHAN Cures Act

Lobbying activity 2

Health Issues

Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.

Medicare/Medicaid

Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.